Corbus Pharmaceuticals Holdings CRBP
NASDAQ CRBP
$4.05 -0.08 (-1.94%)
At close: Oct 23, 2026 · 4:00 PM EDT

Corbus Pharmaceuticals Holdings (CRBP) Gains from Sales and Divestitures (2021)

Updated

Corbus Pharmaceuticals Holdings (CRBP) reported Gains from Sales and Divestitures of -$21,235 for FY2022, compared with -$606,078 in FY2021.

Analysis

Corbus Pharmaceuticals Holdings (CRBP) Gains from Sales and Divestitures (2021) Analysis & Trends

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$606,078 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Corbus Pharmaceuticals Holdings 50.77 Mn -465.86 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -596,979.00
Sep 30, 2021 -1,185.00
Jun 30, 2021 -13,370.00
Mar 31, 2021 5,456.00
API Access

Corbus Pharmaceuticals Holdings Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRBP&period=max&api_key=YOUR_API_KEY